Coherus Oncology (CHRS) Cash from Financing Activities (2014 - 2026)

Coherus Oncology has disclosed Cash from Financing Activities across 13 years of filings, most recently posting $53.6 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $53.6 million, up 20399.24% year-over-year; the trailing twelve-month figure through Mar 2026 was -$219.9 million (down 16.86% YoY), and the FY2025 annual result was -$273.7 million, down 46.39% from the prior year.
• Cash from Financing Activities came in at $53.6 million for Q1 2026 at Coherus Oncology, up from $8.1 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $54.3 million in Q2 2023 to a low of -$281.5 million in Q2 2025.
• The 5-year median for Cash from Financing Activities is $721000.0 (2022), against an average of -$16.7 million.
• Across the five-year window, Cash from Financing Activities tumbled 445.93% in 2024 and surged 20399.24% in 2026, its largest moves.
• Coherus Oncology's Cash from Financing Activities stood at $6.6 million in 2022, then sank by 94.45% to $366000.0 in 2023, then sank by 36.89% to $231000.0 in 2024, then soared by 3398.27% to $8.1 million in 2025, then soared by 563.16% to $53.6 million in 2026.
• The last three Cash from Financing Activities figures came in at $53.6 million (Q1 2026), $8.1 million (Q4 2025), and $2000.0 (Q3 2025), per Business Quant data.